tiprankstipranks
Repligen Corp (DE:RGN)
FRANKFURT:RGN
Germany Market
RGN
Repligen
RESEARCH TOOLSreports

Repligen (RGN) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

RGN Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Repligen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RGN Stock 12 Month Forecast

Average Price Target

€149.67
▲(31.58% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is €149.67 with a high forecast of €179.65 and a low forecast of €125.84. The average price target represents a 31.58% change from the last price of €113.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"€93","180":"€180","114.75":"€114.8","136.5":"€136.5","158.25":"€158.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":179.65116414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€179.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":149.6698543581818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€149.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.8426029,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€125.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,114.75,136.5,158.25,180],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.85,128.14239724153845,132.43479448307693,136.72719172461538,141.01958896615383,145.3119862076923,149.60438344923077,153.89678069076922,158.1891779323077,162.48157517384615,166.7739724153846,171.0663696569231,175.35876689846154,{"y":179.65116414,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.85,125.83614264293706,127.82228528587412,129.80842792881117,131.79457057174824,133.7807132146853,135.76685585762237,137.7529985005594,139.73914114349648,141.72528378643355,143.71142642937062,145.69756907230766,147.68371171524473,{"y":149.6698543581818,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.85,124.00327714615383,124.15655429230769,124.30983143846153,124.46310858461538,124.61638573076922,124.76966287692308,124.92294002307692,125.07621716923077,125.22949431538461,125.38277146153847,125.53604860769231,125.68932575384616,{"y":125.8426029,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.7,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€179.65Average Price Target€149.67Lowest Price Target€125.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:RGN
Brandon Couillard
Wells Fargo
Wells Fargo
€156.22→€160.56
Buy
41.15%
Upside
Reiterated
07/30/26
Wells Fargo Keeps Their Buy Rating on Repligen (RGEN)
Stifel Nicolaus Analyst forecast on DE:RGN
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€179.65
Buy
57.94%
Upside
Reiterated
07/29/26
Analysts' Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)
J.P. Morgan Analyst forecast on DE:RGN
Casey Woodring
J.P. Morgan
J.P. Morgan
€143.2→€151.88
Buy
33.52%
Upside
Assigned
07/29/26
Repligen price target raised to $175 from $165 at JPMorganRepligen price target raised to $175 from $165 at JPMorgan
RBC Capital Analyst forecast on DE:RGN
Dan Leonard
RBC Capital
RBC Capital
€138.86→€160.56
Buy
41.15%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN) and Envista Holdings (NYSE: NVST)
TD Cowen Analyst forecast on DE:RGN
Brendan Smith
TD Cowen
TD Cowen
€173.58
Buy
52.59%
Upside
Reiterated
07/28/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)
Canaccord Genuity Analyst forecast on DE:RGN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
€125.84
Hold
10.63%
Upside
Reiterated
07/28/26
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
William Blair Analyst forecast on DE:RGN
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
07/28/26
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
Barclays Analyst forecast on DE:RGN
Luke Sergott
Barclays
Barclays
€138.86
Buy
22.08%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH), AnaptysBio (NASDAQ: ANAB) and Repligen (NASDAQ: RGEN)
Benchmark Co. Analyst forecast on DE:RGN
Robert Wasserman
Benchmark Co.
Benchmark Co.
€160.56
Buy
41.15%
Upside
Upgraded
07/07/26
Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark
Evercore ISI Analyst forecast on DE:RGN
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
€130.18→€138.86
Buy
22.08%
Upside
Reiterated
07/06/26
Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI
Craig-Hallum Analyst forecast on DE:RGN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
06/24/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
HSBC Analyst forecast on DE:RGN
Yessica Sanchez Gudino
HSBC
HSBC
€147.54→€130.18
Buy
14.45%
Upside
Reiterated
06/03/26
Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC
Wolfe Research Analyst forecast on DE:RGN
Michael Polark
Wolfe Research
Wolfe Research
€125.84
Buy
10.63%
Upside
Initiated
06/01/26
Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research
Guggenheim Analyst forecast on DE:RGN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)
Jefferies Analyst forecast on DE:RGN
Matthew Stanton, CFA
Jefferies
Jefferies
€131.92→€123.24
Hold
8.34%
Upside
Reiterated
05/05/26
Repligen price target lowered to $142 from $152 at JefferiesRepligen price target lowered to $142 from $152 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:RGN
Brandon Couillard
Wells Fargo
Wells Fargo
€156.22→€160.56
Buy
41.15%
Upside
Reiterated
07/30/26
Wells Fargo Keeps Their Buy Rating on Repligen (RGEN)
Stifel Nicolaus Analyst forecast on DE:RGN
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€179.65
Buy
57.94%
Upside
Reiterated
07/29/26
Analysts' Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)
J.P. Morgan Analyst forecast on DE:RGN
Casey Woodring
J.P. Morgan
J.P. Morgan
€143.2→€151.88
Buy
33.52%
Upside
Assigned
07/29/26
Repligen price target raised to $175 from $165 at JPMorganRepligen price target raised to $175 from $165 at JPMorgan
RBC Capital Analyst forecast on DE:RGN
Dan Leonard
RBC Capital
RBC Capital
€138.86→€160.56
Buy
41.15%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN) and Envista Holdings (NYSE: NVST)
TD Cowen Analyst forecast on DE:RGN
Brendan Smith
TD Cowen
TD Cowen
€173.58
Buy
52.59%
Upside
Reiterated
07/28/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)
Canaccord Genuity Analyst forecast on DE:RGN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
€125.84
Hold
10.63%
Upside
Reiterated
07/28/26
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
William Blair Analyst forecast on DE:RGN
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
07/28/26
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
Barclays Analyst forecast on DE:RGN
Luke Sergott
Barclays
Barclays
€138.86
Buy
22.08%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: Community Health (NYSE: CYH), AnaptysBio (NASDAQ: ANAB) and Repligen (NASDAQ: RGEN)
Benchmark Co. Analyst forecast on DE:RGN
Robert Wasserman
Benchmark Co.
Benchmark Co.
€160.56
Buy
41.15%
Upside
Upgraded
07/07/26
Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark
Evercore ISI Analyst forecast on DE:RGN
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
€130.18→€138.86
Buy
22.08%
Upside
Reiterated
07/06/26
Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI
Craig-Hallum Analyst forecast on DE:RGN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
06/24/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
HSBC Analyst forecast on DE:RGN
Yessica Sanchez Gudino
HSBC
HSBC
€147.54→€130.18
Buy
14.45%
Upside
Reiterated
06/03/26
Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC
Wolfe Research Analyst forecast on DE:RGN
Michael Polark
Wolfe Research
Wolfe Research
€125.84
Buy
10.63%
Upside
Initiated
06/01/26
Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research
Guggenheim Analyst forecast on DE:RGN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)
Jefferies Analyst forecast on DE:RGN
Matthew Stanton, CFA
Jefferies
Jefferies
€131.92→€123.24
Hold
8.34%
Upside
Reiterated
05/05/26
Repligen price target lowered to $142 from $152 at JefferiesRepligen price target lowered to $142 from $152 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

3 Months
Luke SergottBarclays
Success Rate
7/9 ratings generated profit
78%
Average Return
+4.23%
Copying Luke Sergott's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +4.23% per trade.
1 Year
Luke SergottBarclays
Success Rate
8/9 ratings generated profit
89%
Average Return
+9.89%
Copying Luke Sergott's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +9.89% per trade.
2 Years
Luke SergottBarclays
Success Rate
8/9 ratings generated profit
89%
Average Return
+11.48%
Copying Luke Sergott's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +11.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
5
4
4
0
Buy
14
9
13
20
16
Hold
3
4
4
5
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
18
21
29
18
In the current month, RGN has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RGN average Analyst price target in the past 3 months is 149.67.
Each month's total comprises the sum of three months' worth of ratings.

RGN Financial Forecast

RGN Earnings Forecast

Next quarter’s earnings estimate for RGN is €0.40 with a range of €0.36 to €0.42. The previous quarter’s EPS was €0.47. RGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for RGN is €0.40 with a range of €0.36 to €0.42. The previous quarter’s EPS was €0.47. RGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.

RGN Sales Forecast

Next quarter’s sales forecast for RGN is €179.31M with a range of €177.76M to €180.53M. The previous quarter’s sales results were €177.00M. RGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.
Next quarter’s sales forecast for RGN is €179.31M with a range of €177.76M to €180.53M. The previous quarter’s sales results were €177.00M. RGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year RGN has Performed in-line its overall industry.

RGN Stock Forecast FAQ

What is DE:RGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Repligen Corp’s 12-month average price target is 149.67.
    What is DE:RGN’s upside potential, based on the analysts’ average price target?
    Repligen Corp has 31.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Repligen Corp a Buy, Sell or Hold?
          Repligen Corp has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Repligen Corp’s share price target?
            The average share price target for Repligen Corp is 149.67. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €179.65 ,and the lowest forecast is €125.84. The average share price target represents 31.58% Increase from the current price of €113.75.
              What do analysts say about Repligen Corp?
              Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Repligen Corp?
                To buy shares of DE:RGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.